- Home
- NRXS vs NNVC Comparison
NRXS vs NNVC Comparison
Compare NRXS & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- NNVC
- Stock Information
- Founded
- NRXS 2011
- NNVC 2005
- Country
- NRXS United States
- NNVC United States
- Employees
- NRXS N/A
- NNVC N/A
- Industry
- NRXS
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- NNVC Health Care
- Exchange
- NRXS Nasdaq
- NNVC Nasdaq
- Market Cap
- NRXS 25.0M
- NNVC 22.5M
- IPO Year
- NRXS 2023
- NNVC N/A
- Fundamental
- Price
- NRXS $2.43
- NNVC $1.49
- Analyst Decision
- NRXS Strong Buy
- NNVC
- Analyst Count
- NRXS 1
- NNVC 0
- Target Price
- NRXS $7.00
- NNVC N/A
- AVG Volume (30 Days)
- NRXS 52.6K
- NNVC 130.0K
- Earning Date
- NRXS 08-12-2025
- NNVC 09-26-2025
- Dividend Yield
- NRXS N/A
- NNVC N/A
- EPS Growth
- NRXS N/A
- NNVC N/A
- EPS
- NRXS N/A
- NNVC N/A
- Revenue
- NRXS $3,217,531.00
- NNVC N/A
- Revenue This Year
- NRXS $62.14
- NNVC N/A
- Revenue Next Year
- NRXS $131.87
- NNVC N/A
- P/E Ratio
- NRXS N/A
- NNVC N/A
- Revenue Growth
- NRXS 41.93
- NNVC N/A
- 52 Week Low
- NRXS $1.33
- NNVC $0.94
- 52 Week High
- NRXS $6.20
- NNVC $1.92
- Technical
- Relative Strength Index (RSI)
- NRXS 46.52
- NNVC 51.75
- Support Level
- NRXS $2.35
- NNVC $1.40
- Resistance Level
- NRXS $2.68
- NNVC $1.54
- Average True Range (ATR)
- NRXS 0.13
- NNVC 0.07
- MACD
- NRXS 0.01
- NNVC 0.00
- Stochastic Oscillator
- NRXS 41.59
- NNVC 65.22
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.